Because evidence gaps in idiopathic pulmonary fibrosis research hinder demonstration of antifibrotic therapies’ impact on patient quality of life (QOL), integrating validated health-related QOL measures into trials is urgently needed.
Franco Nicolae Grados Rodriguez
Advertisement
Articles by Franco Nicolae Grados Rodriguez
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Flatiron’s AI-Driven Telescope Makes Data Access More User-Friendly
2
Legend Biotech’s CAR T-cell Therapy Shows Early Promise in SCLC, Other Tumors
3
Social Factors May Match, Outpace Genetic Risk in Disease Prediction
4
Long-Term, Consistent Resistance Training Linked to Substantially Lower Type 2 Diabetes Risk
5